PPARalpha-mediated effects of dietary lipids on intestinal barrier gene expression

BackgroundThe selective absorption of nutrients and other food constituents in the small intestine is mediated by a group of transport proteins and metabolic enzymes, often collectively called 'intestinal barrier proteins'. An important receptor that mediates the effects of dietary lipids on gene expression is the peroxisome proliferator-activated receptor alpha (PPARα), which is abundantly expressed in enterocytes. In this study we examined the effects of acute nutritional activation of PPARα on expression of genes encoding intestinal barrier proteins. To this end we used triacylglycerols composed of identical fatty acids in combination with gene expression profiling in wild-type and PPARα-null mice. Treatment with the synthetic PPARα agonist WY14643 served as reference.ResultsWe identified 74 barrier genes that were PPARα-dependently regulated 6 hours after activation with WY14643. For eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and oleic acid (OA) these numbers were 46, 41, and 19, respectively. The overlap between EPA-, DHA-, and WY14643-regulated genes was considerable, whereas OA treatment showed limited overlap. Functional implications inferred form our data suggested that nutrient-activated PPARα regulated transporters and phase I/II metabolic enzymes were involved in a) fatty acid oxidation, b) cholesterol, glucose, and amino acid transport and metabolism, c) intestinal motility, and d) oxidative stress defense.ConclusionWe identified intestinal barrier genes that were PPARα-dependently regulated after acute activation by fatty acids. This knowledge provides a better understanding of the impact dietary fat has on the barrier function of the gut, identifies PPARα as an important factor controlling this key function, and underscores the importance of PPARα for nutrient-mediated gene regulation in intestine.

[1]  M. Palacín,et al.  CATs and HATs: the SLC7 family of amino acid transporters , 2004, Pflügers Archiv.

[2]  J. Mandel,et al.  Fenofibrate differently alters expression of genes encoding ATP‐binding transporter proteins of the peroxisomal membrane , 1997, FEBS letters.

[3]  Michael Müller,et al.  Gene expression of transporters and phase I/II metabolic enzymes in murine small intestine during fasting , 2007, BMC Genomics.

[4]  D. Townsend,et al.  The importance of glutathione in human disease. , 2003, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  Kendall W Nettles,et al.  Ligand control of coregulator recruitment to nuclear receptors. , 2005, Annual review of physiology.

[6]  Peter J. Brown,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .

[7]  Andreas Rolfs,et al.  The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins , 2004, Pflügers Archiv.

[8]  S. Kersten,et al.  Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. , 2006, Endocrinology.

[9]  R. Ringseis,et al.  Treatment with pharmacological peroxisome proliferator-activated receptor alpha agonist clofibrate causes upregulation of organic cation transporter 2 in liver and small intestine of rats. , 2007, Pharmacological research.

[10]  Igor Jurisica,et al.  Integrated proteomic and transcriptomic profiling of mouse lung development and Nmyc target genes , 2022 .

[11]  Ferdinando Palmieri,et al.  The mitochondrial transporter family (SLC25): physiological and pathological implications , 2004, Pflügers Archiv.

[12]  R. Tukey,et al.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease. , 2000, Annual review of pharmacology and toxicology.

[13]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[14]  K. Inui,et al.  Induction of intestinal peptide transporter 1 expression during fasting is mediated via peroxisome proliferator-activated receptor alpha. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[15]  Vincent Laudet,et al.  Overview of Nomenclature of Nuclear Receptors , 2006, Pharmacological Reviews.

[16]  P Tso,et al.  Intestinal lipid absorption and transport. , 2001 .

[17]  J. Okita,et al.  Cytochrome P450 4A fatty acid omega hydroxylases. , 2001, Current drug metabolism.

[18]  G. Francis,et al.  Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. , 1995, The Journal of clinical investigation.

[19]  B. Staels,et al.  Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1 Published, JLR Papers in Press, December 16, 2004. DOI 10.1194/jlr.M400400-JLR200 , 2005, Journal of Lipid Research.

[20]  A. Wakamatsu,et al.  SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. , 2005, Life sciences.

[21]  E. Banoglu Current status of the cytosolic sulfotransferases in the metabolic activation of promutagens and procarcinogens. , 2000, Current drug metabolism.

[22]  J. Lehmann,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Jasmine Chen,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  E. Mazzon,et al.  Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-α) in the development of inflammatory bowel disease in mice , 2004, Laboratory Investigation.

[25]  B. Miroux,et al.  A New Renal Mitochondrial Carrier, KMCP1, Is Up-regulated during Tubular Cell Regeneration and Induction of Antioxidant Enzymes* , 2005, Journal of Biological Chemistry.

[26]  B. Lanne,et al.  Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat. , 2007, American journal of physiology. Endocrinology and metabolism.

[27]  Robin Hull,et al.  A good practice guide to the administration of substances and removal of blood, including routes and volumes , 2001, Journal of applied toxicology : JAT.

[28]  R. Weinshilboum,et al.  Sulfotransferase molecular biology: cDNAs and genes , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  C. Thompson,et al.  Protein expression, characterization, and regulation of CYP4F4 and CYP4F5 cloned from rat brain. , 1997, Archives of biochemistry and biophysics.

[30]  K. Suckling,et al.  Synthesis and coenzyme A-dependent esterification of cholesterol in rat intestinal epithelium. Differences in cellular localization and mechanisms of regulation. , 1983, The Journal of biological chemistry.

[31]  K. Motojima,et al.  PPARalpha agonists positively and negatively regulate the expression of several nutrient/drug transporters in mouse small intestine. , 2007, Biological & pharmaceutical bulletin.

[32]  L. Kaminsky,et al.  The small intestine as a xenobiotic-metabolizing organ. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[33]  J. Falck,et al.  Oxygenation of omega-3 fatty acids by human cytochrome P450 4F3B: effect on 20-hydroxyeicosatetraenoic acid production. , 2006, Prostaglandins, leukotrienes, and essential fatty acids.

[34]  L. Benet,et al.  Active secretion and enterocytic drug metabolism barriers to drug absorption. , 2001, Advanced drug delivery reviews.

[35]  W. Wahli,et al.  The peroxisome proliferator‐activated receptor α regulates amino acid metabolism , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  M. Uldry,et al.  The SLC2 family of facilitated hexose and polyol transporters , 2004, Pflügers Archiv.

[37]  T. Pineau,et al.  Fibrate induction of the adrenoleukodystrophy-related gene (ABCD2): promoter analysis and role of the peroxisome proliferator-activated receptor PPARalpha. , 2001, European journal of biochemistry.

[38]  T. Langmann,et al.  Structure, function and regulation of the ABC1 gene product , 2001, Current opinion in lipidology.

[39]  F. Bredin,et al.  Evidence for association of OCTN genes and IBD5 with ulcerative colitis , 2005, Gut.

[40]  G. Gibbons,et al.  Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. , 2003, Journal of lipid research.

[41]  P. Potin,et al.  Human CYP4F3s are the main catalysts in the oxidation of fatty acid epoxidess⃞s⃞ The online version of this article (available at http://www.jlr.org) contains an additional four tables and six figures. Published, JLR Papers in Press, May 16, 2004. DOI 10.1194/jlr.M300463-JLR200 , 2004, Journal of Lipid Research.

[42]  F. Martel Recent advances on the importance of the serotonin transporter SERT in the rat intestine. , 2006, Pharmacological research.

[43]  S. Bowman,et al.  Dietary-fat intake in the US population. , 1999, Journal of the American College of Nutrition.

[44]  M. Hediger,et al.  Primary structure and functional characterization of a high-affinity glutamate transporter , 1992, Nature.

[45]  H. Rosing,et al.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[46]  K. Tew,et al.  GST function in drug and stress response. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[47]  W. Sigurdson,et al.  Polarized localization of vitamin C transporters, SVCT1 and SVCT2, in epithelial cells. , 2005, Biochemical and biophysical research communications.

[48]  P. Watkins,et al.  Human very-long-chain acyl-CoA synthetase: cloning, topography, and relevance to branched-chain fatty acid metabolism. , 1999, Biochemical and biophysical research communications.

[49]  P. Hunziker,et al.  Basolateral aromatic amino acid transporter TAT1 (Slc16a10) functions as an efflux pathway , 2006, Journal of cellular physiology.

[50]  Aurélien Grosdidier,et al.  The Endocrine Disruptor Monoethyl-hexyl-phthalate Is a Selective Peroxisome Proliferator-activated Receptor γ Modulator That Promotes Adipogenesis* , 2007, Journal of Biological Chemistry.

[51]  H. Sampath,et al.  Polyunsaturated fatty acid regulation of genes of lipid metabolism. , 2005, Annual review of nutrition.

[52]  D. Markovich,et al.  The SLC13 gene family of sodium sulphate/carboxylate cotransporters , 2004, Pflügers Archiv.

[53]  Danielson Pb,et al.  The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002 .

[54]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[55]  G. Hooiveld,et al.  Genome-wide analysis of PPARα activation in murine small intestine , 2007 .

[56]  H. Waterham,et al.  The peroxisomal ABC transporter family , 2007, Pflügers Archiv - European Journal of Physiology.

[57]  Karim Benkirane,et al.  Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. , 2003, Hypertension.

[58]  B. Spiegelman,et al.  International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors , 2006, Pharmacological Reviews.

[59]  W. Wahli,et al.  Fluorescence Imaging Reveals the Nuclear Behavior of Peroxisome Proliferator-activated Receptor/Retinoid X Receptor Heterodimers in the Absence and Presence of Ligand*♦ , 2005, Journal of Biological Chemistry.

[60]  J. Lehmann,et al.  Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. , 2000, Molecular cell.

[61]  T. Murase,et al.  Dietary alpha-linolenic acid-rich diacylglycerols reduce body weight gain accompanying the stimulation of intestinal beta-oxidation and related gene expressions in C57BL/KsJ-db/db mice. , 2002, The Journal of nutrition.

[62]  T. Murase,et al.  Dietary α-Linolenic Acid–Rich Diacylglycerols Reduce Body Weight Gain Accompanying the Stimulation of Intestinal β-Oxidation and Related Gene Expressions in C57BL/KsJ-db/db Mice , 2002 .

[63]  W. Wahli,et al.  Transcriptional regulation of metabolism. , 2006, Physiological reviews.

[64]  S. Antonarakis,et al.  The human sugar-phosphate/phosphate exchanger family SLC37 , 2004, Pflügers Archiv.

[65]  J. Moscow,et al.  Glutathione-related enzymes, glutathione and multidrug resistance , 2004, Cytotechnology.

[66]  H. Lodish,et al.  Identification of the major intestinal fatty acid transport protein. , 1999, Molecular cell.

[67]  H. C. Lee,et al.  Mitochondrial role in life and death of the cell. , 2000, Journal of biomedical science.

[68]  J. Schuetz,et al.  The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme* , 2004, Journal of Biological Chemistry.

[69]  P. Danielson,et al.  The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002, Current drug metabolism.

[70]  A. Rettie,et al.  Positional specificity of rabbit CYP4B1 for omega-hydroxylation1 of short-medium chain fatty acids and hydrocarbons. , 1998, Biochemical and biophysical research communications.

[71]  P. Tso,et al.  Intestinal lipid absorption and transport. , 2001, Frontiers in bioscience : a journal and virtual library.

[72]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[73]  S. Kersten,et al.  Peroxisome proliferator-activated receptor alpha target genes. , 2004, Cellular and molecular life sciences : CMLS.

[74]  F. Oesch,et al.  Epoxide hydrolases: structure, function, mechanism, and assay. , 2005, Methods in enzymology.

[75]  P. Borst,et al.  Mammalian ABC transporters in health and disease. , 2002, Annual review of biochemistry.

[76]  S. Kersten,et al.  Nutrigenomics: goals and strategies , 2003, Nature Reviews Genetics.

[77]  J. Hoeijmakers,et al.  Dysregulation of the Peroxisome Proliferator-Activated Receptor Target Genes by XPD Mutations , 2005, Molecular and Cellular Biology.

[78]  Richard A Gibbs,et al.  Genomic analysis of the nuclear receptor family: new insights into structure, regulation, and evolution from the rat genome. , 2004, Genome research.

[79]  R. Gebhard,et al.  In vivo regulation of canine intestinal 3-hydroxy-3-methylglutaryl coenzyme A reductase by cholesterol, lipoprotein, and fatty acids. , 1981, Journal of lipid research.

[80]  K. Motojima,et al.  PPARα Agonists Positively and Negatively Regulate the Expression of Several Nutrient/Drug Transporters in Mouse Small Intestine , 2007 .

[81]  W. Roediger,et al.  Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation. , 1986, British journal of experimental pathology.

[82]  H. Kondo,et al.  Differential regulation of intestinal lipid metabolism-related genes in obesity-resistant A/J vs. obesity-prone C57BL/6J mice. , 2006, American journal of physiology. Endocrinology and metabolism.

[83]  D. Waxman,et al.  Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. , 1995, Archives of biochemistry and biophysics.

[84]  K. Siminovitch,et al.  A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's disease. , 2005, Gastroenterology.

[85]  M. Relling,et al.  Nomenclature for N-acetyltransferases. , 1995, Pharmacogenetics.

[86]  D. Meredith,et al.  The SLC16 gene family—from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond , 2004, Pflügers Archiv.

[87]  C. Glass,et al.  PPARs and molecular mechanisms of transrepression. , 2007, Biochimica et biophysica acta.

[88]  Y. Kato,et al.  Organic Cation/Carnitine Transporter OCTN2 (Slc22a5) Is Responsible for Carnitine Transport across Apical Membranes of Small Intestinal Epithelial Cells in Mouse , 2006, Molecular Pharmacology.

[89]  J. Peters,et al.  Polyunsaturated Fatty Acid Suppression of Hepatic Fatty Acid Synthase and S14 Gene Expression Does Not Require Peroxisome Proliferator-activated Receptor α* , 1997, The Journal of Biological Chemistry.

[90]  C. Glass,et al.  Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators , 1998, Nature.

[91]  S. Ferdinandusse,et al.  PPAR alpha-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation. , 2007, Biochimica et biophysica acta.

[92]  S. A. Tariq Role of Ascorbic Acid in Scavenging Free Radicals and Lead Toxicity from Biosystems , 2007, Molecular biotechnology.

[93]  R. Gainetdinov,et al.  Mice lacking the dopamine transporter display altered regulation of distal colonic motility. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[94]  M. Hayden,et al.  ABCA1 Is Essential for Efficient Basolateral Cholesterol Efflux during the Absorption of Dietary Cholesterol in Chickens* , 2003, The Journal of Biological Chemistry.

[95]  Luquan Wang,et al.  Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Niemann-pick C1 like 1 Protein Is Critical for Intestinal Cholesterol Absorption , 2022 .

[96]  P. Hjemdahl,et al.  Concentration-dependent stimulation of intestinal phase III of migrating motor complex by circulating serotonin in humans. , 1998, Clinical science.

[97]  C. Liu,et al.  Bacterial expression, purification, and characterization of a novel mouse sulfotransferase that catalyzes the sulfation of eicosanoids. , 1999, Biochemical and biophysical research communications.

[98]  S. Gaetani,et al.  Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α , 2003, Nature.

[99]  H. Daniel,et al.  The SLC36 family: proton-coupled transporters for the absorption of selected amino acids from extracellular and intracellular proteolysis , 2004, Pflügers Archiv.

[100]  A. Ciccodicola,et al.  Experimental colitis: decreased Octn2 and Atb0+ expression in rat colonocytes induces carnitine depletion that is reversible by carnitine‐loaded liposomes , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[101]  E. Wright,et al.  The sodium/glucose cotransport family SLC5 , 2004, Pflügers Archiv.

[102]  J. Repa,et al.  Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. , 2007, Journal of lipid research.

[103]  W. Wahli,et al.  Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. , 1997, Molecular endocrinology.

[104]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[105]  S. Kersten,et al.  Peroxisome proliferator-activated receptor α target genes , 2004, Cellular and Molecular Life Sciences CMLS.

[106]  F. Field,et al.  LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells DOI 10.1194/jlr.M100358-JLR200 , 2002, Journal of Lipid Research.

[107]  J. G. Bieri Second Report of the ad hoc Committee on Standards for Nutritional Studies , 1980 .

[108]  A. Pajor Sodium-coupled transporters for Krebs cycle intermediates. , 1999, Annual review of physiology.

[109]  Michelle S. Scott,et al.  Global Survey of Organ and Organelle Protein Expression in Mouse: Combined Proteomic and Transcriptomic Profiling , 2006, Cell.